Published in final edited form as:

Cancer. 2008 October 1; 113(7 0): 1911–1932. doi:10.1002/cncr.23654.

Head and Neck Cancer: An Evolving Treatment Paradigm

David M. Cignetti, MD¹, Randal S. Weber, MD², and Stephen Y. Lai, MD, PhD^{1,2,3}

¹ Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

² Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, University of Texas, Houston, Texas

³ Department of Pharmacology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Abstract

Since the inception of this journal in 1948, the understanding of etiologic factors that contribute to and the treatment of head and neck cancer has evolved dramatically. Advances in surgery, radiation therapy, and chemotherapy have improved locoregional control, survival, and quality of life. The outcomes of these treatment modalities have shifted the focus of curative efforts from radical ablation to preservation and restoration of function. This evolution has been documented in the pages of *Cancer* for the past 6 decades. This review focuses on the evolution of treatment approaches for head and neck cancer and future directions while recognizing the historic contributions recorded within this journal.

Keywords

head and neck cancer; head and neck squamous cell carcinoma (HNSCC); head and neck surgery; neck dissection; radiation therapy; combined modality therapy; concurrent chemotherapy

Head and neck cancer includes epithelial malignancies of the upper aerodigestive tract (UADT), including the paranasal sinuses, nasal cavity, oral cavity, pharynx, and larynx; and, as the sixth most common cancer worldwide, head and neck cancer represents about 6% of solid tumors. Approximately 650,000 new head and neck cancers are diagnosed annually, and there are 350,000 deaths yearly worldwide.¹ In the United States, head and neck cancer accounted for approximately 45,660 new cancer cases in 2007, corresponding to 3% of all new cancer diagnoses in this country.² Almost 66% of patients present with advanced-stage disease. Despite advances in treatment options, approximately 11,210 head and neck cancer-related deaths occurred during 2007 in the United States.² The median age of diagnosis is in the sixth decade of life, and there is a large male-to-female predominance.¹ Although there has been a slight decrease in overall incidence of head and neck cancer over the past 2 decades,³ an increase in base of tongue and tonsillar cancer recently has been observed.⁴

Address for reprints: Stephen Y. Lai, MD, PhD, Department of Head and Neck Surgery, Unit 1445, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030; Fax: (713) 794-4662; stephenlai@gmail.com.
David M. Cignetti's current address: Department of Otolaryngology, Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.

Etiology

In the inaugural year of *Cancer*, Morton Levin documented sex disparity in cancers of the UADT as well as a rapidly increasing incidence of lung cancer during the 1930s.⁵ Despite providing detailed reviews of factors like age, socioeconomic position, and carcinogenic chemicals and radiation, the contribution of tobacco to these cancers never was mentioned. In 1953, Slaughter and colleagues introduced the concept of ‘field cancerization’ in squamous cell carcinoma of the oral cavity (Fig. 1).⁶ That landmark article provided a rationale for the high rate of second primary cancers in patients with head and neck squamous cell carcinoma (HNSCC). In their report, Slaughter et al suggested that the oral epithelium is preconditioned by an ‘as-yet-unknown carcinogenic agent.’ Again, the role of tobacco was not recognized.

Today, it seems difficult to imagine a time when tobacco and cancer were not causally linked. The Surgeon General’s report of 1964 called public attention to the increasing amount of definitive evidence linking tobacco use and cancer.⁷ In 1954, Watson and Conte published a report on 301 patients with lung cancer and reviewed the available evidence.⁸ They concluded that cigarette smoking likely represents an additional carcinogenic factor in squamous cell carcinoma of the lung. It is noteworthy that 90% of the patients in their control group were smokers, highlighting the prevalence of tobacco use at that time. In fact, many tobacco promotional advertisements of that era featured physicians.⁹ Ernest Wynder of the Sloan-Kettering Institute of Cancer Research was the lead author of an 11-part experimental series demonstrating tobacco carcinogenesis in mice that was published in *Cancer* between 1957 and 1971.^{10–20} Wynder and colleagues also published reviews that demonstrated the causative roles of tobacco and alcohol in oral cavity, laryngeal, and esophageal cancers.^{21–24} In 1962, Vogler and colleagues similarly linked tobacco to cancer of the mouth, pharynx, and larynx.²⁵ Today, tobacco use is accepted universally as a causative factor for HNSCC. In addition, it has been demonstrated that alcohol also increases the chance of head and neck cancer, and the combined risk of tobacco and alcohol use has synergism beyond their simple additive risk.^{26–28}

More recently, human papillomavirus (HPV) has been recognized as an important independent risk factor in HNSCC. One of the earliest reports to recognize a molecular association between HPV and HNSCC was published in *Cancer*.²⁹ Approximately 25% of HNSCC specimens contain HPV genomic DNA, primarily HPV type 16 and, less frequently, type 18.³⁰ Expression of the E6 and E7 viral oncoproteins inactivate the tumor-suppressor proteins p53 and Rb, respectively.³¹ Subsite analysis within the head and neck demonstrated that HPV is associated most commonly with oropharyngeal tumors, especially of the tonsil, with HPV DNA identified in up to 60% of specimens.^{32–34} Certain high-risk sexual behaviors have been associated with HPV transmission and oropharyngeal carcinoma.^{35,36} The association of HPV and HNSCC has important implications regarding prevention, treatment, and prognosis. The presence of HPV may be a favorable prognostic factor in HNSCC, especially in patients with no history of tobacco and/or alcohol use, possibly because of increased radiosensitivity.^{37,38} HPV-positive, locally advanced HNSCC tumors may respond well to standard therapy and may not require treatment

intensification. In addition, the role of vaccination against HPV in HNSCC remains to be explored.

Evolution of Treatment for Head and Neck Squamous Cell Carcinoma

At the turn of the last century, radiation had just been discovered, and surgical outcomes were hampered by the lack of antibiotics and the limitations of anesthesia. For these reasons, there was a tendency to use radiation therapy (RT) as primary treatment for the first half of the 20th century. In the middle 20th century, advancements in perioperative care, combined with the recognized side effects and treatment failures of early RT techniques, led to the emergence of primary surgical treatment with or without adjuvant RT for most head and neck cancers. Subsequent advancements in RT improved cure rates and decreased toxicities. Today, RT remains an important single-modality option in early-stage cancers and plays an important role in the adjuvant setting. In the second half of the 20th century, a focus on functional outcomes and an increasing role of chemotherapy led to both surgical and nonsurgical organ-preservation approaches. Recently, combinations of chemotherapy and RT have been used increasingly for advanced-stage cancers, both for primary and adjuvant treatment. Finally, the development of targeted molecular therapies offers new options in the management of HNSCC, which may further improve survival and functional results.

Surgical Treatment

The surgical management of head and neck cancer evolved rapidly during the history of this journal because of improvements in anesthesia, development of antibiotics and blood banking, and introduction of new techniques for reconstruction. Radical resection has given way to the goal of cure with preservation of function. Changing strategies in the surgical management of the neck and larynx in patients with HNSCC highlight this point.

Neck dissection

In 1951, Hayes Martin and colleagues' landmark report on neck dissection was published in *Cancer*.³⁹ That report comprehensively reviewed the treatment of HNSCC cervical metastases. Although George Crile first described an en bloc dissection of the cervical lymphatics in 1906,⁴⁰ the report by Martin et al is considered the greatest impetus to the popular adoption of the radical neck dissection (RND) (Fig. 2).⁴¹ Martin et al reported their experience with 1450 neck dissections performed at Memorial Hospital between 1928 and 1950. Whereas Crile reported preservation of the spinal accessory nerve (SAN) when the nerve was not involved with tumor, Martin insisted that "any technique designed to preserve the spinal accessory nerve should be condemned unequivocally."³⁹ With Martin's report, RND with sacrifice of the internal jugular vein (IJV,) sternocleidomastoid muscle (SCM), and SAN became the surgical procedure of choice for clinically positive necks (Fig. 3). Martin did not advocate prophylactic dissection of the clinically negative neck, instead maintaining close follow-up observation and performing RND if lymph node disease became apparent clinically, acknowledging that RND was too 'radical' for elective use.^{39,42,43}

In 1963, Oswaldo Suarez described a technique for cervical lymphadenectomy in the Spanish-language literature that has become the modified RND (MRND).^{41,44} This technique permitted effective fascial compartment dissection of the cervical lymph nodes with preservation of the nonlymphatic structures (IJV, SAN, and SCM), improving function and cosmesis. Bocca and coworkers introduced this technique in the English-language literature, leading to its popularization.^{45,46} Advantages noted were the minimal surgical side effects in the elective management of clinically negative necks and the ability to perform simultaneous bilateral neck dissections without the risk of facial and cerebral edema seen with bilateral sacrifice of the IJVs.⁴⁷

Given the effectiveness and decreased morbidity of MRND, interest in elective neck dissection (END) was renewed. In 1962, a study published in *Cancer* demonstrated that the regional failure rate was >50% for patients with early tongue cancers who had no clinically evident metastases and whose necks were managed by follow-up observation.⁴⁸ Only 25% of these patients were salvaged for cure. In 1980, the first randomized clinical trial to compare the elective and the 'wait-and-see' therapeutic approaches of RND in oral cavity cancer was published.⁴⁹ That study was limited by a small sample size (n = 75) and failed to demonstrate a difference in survival between the 2 approaches. However, the authors noted that the rate of occult metastases in the END group was 49%, and the rate of eventual lymph node involvement in the observation group was 47%. They concluded that END was advisable in patients who could not be followed regularly and suggested that an MRND was sufficient in this setting. Bocca and colleagues demonstrated that elective MRND had a much lower rate of recurrence compared with elective RND because of the ability to perform bilateral dissection in the MRND group.⁴⁷ Surgeons soon began to perform elective MRND for patients with HNSCC with an occult metastasis rate 20%.⁴³

Since the introduction of MRND, the trend toward conservative surgery has continued. A landmark study that established the clinical rationale for selective neck dissection (SND) was published in *Cancer* in 1972.⁵⁰ Lindberg and colleagues reviewed the records of 2044 HNSCC patients at the University of Texas at Houston M. D. Anderson Hospital and Tumor Institute to identify distribution patterns for cervical metastases clinically apparent at presentation. He demonstrated that metastases from subsites within the head and neck follow predictable patterns to specific lymph node levels within the neck. In 1990, Jatin Shah and colleagues at Memorial-Sloan Kettering Cancer Center evaluated the histologic patterns of lymph node metastasis in patients undergoing elective and therapeutic RND for head and neck cancer.^{51,52} On the basis of these patterns of metastasis, elective dissection of select lymph node levels most at risk was offered as an alternative to elective MRND. In addition, extracapsular spread (ECS) was identified as the most important negative prognostic factor.^{53–56} It was demonstrated that ECS was present even in small, positive lymph nodes and was identified in 20% of clinically negative necks in patients with supraglottic cancer who underwent END.⁵⁶ Pathologic findings on END, including ECS and multiple positive lymph nodes, became indications for postoperative RT and, eventually, chemotherapy.^{57,58} Although the initial movement toward END and MRND was to avoid the functional and cosmetic issues associated with RND, the additional utility of END as a staging procedure soon was recognized.^{43,59} In the 1990s, several studies demonstrated that SND was as

effective as MRND and RND when used to electively treat and stage the clinically negative neck.⁶⁰ Recent studies have suggested that SND can be used safely in patients with limited, clinically positive lymph node disease.^{61–63}

The overarching principle in the evolution of the surgical management of the regional lymphatics in HNSCC has been disease detection and eradication with cosmetic and functional preservation. Sentinel lymph node biopsy (SLNB) has been proposed as an even more selective approach to the pathologic staging of the N0 neck in HNSCC compared with END. Gould and colleagues introduced the concept of SLNB in *Cancer* in 1960.⁶⁴ Those authors described using an intraoperative frozen section of a facial lymph node during parotid surgery to determine whether a neck dissection should be performed for malignant tumors. Currently, SLNB with the use of a radiotracer to identify the sentinel lymph node is accepted as the standard of care in the treatment of breast cancer and melanoma. In 2001, a report in *Cancer* suggested that SLNB in HNSCC is accurate for staging the N0 neck.⁶⁵ Multicenter trials investigating SLNB in the N0 neck for early-stage oral cavity cancer currently are in progress.⁶⁶ Finally, an endoscopic approach to a lateral neck dissection has been described in a porcine model and in humans with papillary thyroid cancer.^{67,68} In addition, it has been demonstrated that the combination of an endoscopic approach with SLNB is feasible in pigs.^{69,70} These minimally invasive, highly selective techniques may play a role in the future staging of patients with HNSCC, especially because the ability to identify occult tumors is likely to improve with new methods to detect molecular markers.

Surgery for laryngeal cancer

At the beginning of the 20th century, lack of early diagnosis, anesthetic limitations, and a high surgical mortality rate made laryngeal carcinoma a hopeless situation in which most patients refused to submit to major surgery because of the small hope for perioperative survival and less likelihood for cure.⁷¹ In this setting, RT was a welcome addition to the treatment armamentarium and became the primary treatment for laryngeal cancer. By the inaugural issue of *Cancer*, the limitations of early RT techniques were recognized, and improvements in surgical techniques and perioperative care led to a ‘reversion’ to extensive surgery as the treatment of choice for laryngeal cancer with regard to laryngectomy and neck dissection.⁷² Hayes Martin noted a rapid increase in the number of laryngectomies performed in the United States during the first 5 years of this journal.⁷³

At the same time, the knowledge of laryngeal anatomy was increasing through important experimental and observational work identifying the anatomic basis for the dissemination of cancer within the larynx as well as to cervical lymph nodes. Pressman et al recognized the highly compartmentalized organization of the larynx and identified the importance of this feature with regard to ‘subtotal laryngectomies.’⁷⁴ In addition to existing open cordectomy and vertical partial laryngectomy, new approaches to partial laryngectomy emerged. The supraglottic laryngectomy was introduced in 1947 and was followed by the supracricoid laryngectomy in 1959.^{75,76} The goals of these procedures are to obtain cure through a less radical means while maintaining the functions of speech and swallow without a permanent stoma.⁷⁷ In 1966, MacComb noted that the functional results were commanding as much attention as the curative results but that the cure had to remain the primary goal.⁷⁸ In 1972,

the carbon dioxide (CO₂) laser was introduced for transoral resection of early laryngeal tumors, and it has produced cure rates equivalent to those achieved with open surgical approaches and RT.^{79,80} Endoscopic laser resection has been extended since then to include select, larger tumors. Recently, the feasibility of a robot-assisted supraglottic laryngectomy with and without the CO₂ laser has been demonstrated, which may expand further the indications for transoral laryngeal cancer resection.^{81,82}

Reconstruction

In 1948, reconstruction and rehabilitation options were limited, and early descriptions in *Cancer* included skin grafting and local tissue flaps, which required multiple procedures.^{83,84} Patients typically were left with significant functional and cosmetic defects. Reconstruction of the oral cavity often consisted of intentional temporary oral-cutaneous fistulae, and fear of making a patient a ‘facial cripple’ was considered a deterrent to adequate surgical treatment of intraoral cancer.⁸⁵ Implanted metallic prostheses for mandible defects were introduced to avoid the ‘Andy Gump’ deformity with its associated difficulty in swallowing and speaking.⁸⁶ These plates were a temporary means to prevent contracture of the muscles of mastication before planned secondary reconstruction with a free bone graft, although most patients died of recurrence before successful reconstruction.^{85,86} Reconstruction of the pharynx and cervical esophagus was a particularly difficult problem and was complicated by high rates of wound breakdown, fistula, and stricture. Attempts at reconstruction with external diversion and secondary reconstruction with skin-lined local flaps or split-thickness skin graft-covered stents were considered palliative because of the poor prognosis of these patients.⁸⁷ Alternatively, a closed pharyngeal pouch was offered after laryngectomy when the surgical defect could not be closed.⁸⁸

A major advance in head and neck reconstruction occurred in 1965, when Bakamjian introduced the deltopectoral flap.⁸⁹ This regional, pedicled, cutaneous flap allowed for reliable reconstruction of the pharynx and cervical esophagus. It was versatile and expanded the capabilities of head and neck reconstruction. However, limitations included the need for a skin graft at the donor site, requirement of a second stage for separation of the pedicle, lack of bulk for larger defects, and insufficient length to reach defects of the upper face and orbit. In 1977, McCraw et al recognized axial patterns for the blood supply of regional flaps and demonstrated the vascular territories for 13 myocutaneous flaps.⁹⁰ In 1979, Ariyan introduced the pectoralis major myocutaneous flap, which overcame the limitations of Bakamjian’s deltopectoral flap.⁹¹ The pectoralis major flap is available to reconstruct defects as high as the orbit and cranial base; and, given its reliability and versatility, the flap quickly became a ‘workhorse’ in head and neck reconstruction.

The biggest advance in head and neck reconstruction has been the introduction and acceptance of microvascular free flaps in the 1980s and 1990s. The radial forearm fasciocutaneous free flap that was introduced in China by Yang and popularized by Soutar et al for head and neck reconstruction revolutionized intraoral reconstruction.^{92,93} The fibula free flap permitted reliable primary bony reconstruction of the mandible.⁹⁴ A wide array of microvascular free flaps now exist and have greatly improved the options and outcomes in head and neck reconstruction.^{95,96}

Other surgical advances

Novel approaches beyond the lateral neck and larynx continue to develop with the goal of limiting cosmetic and functional consequences. Endoscopic sinus surgery provided the basis for expanded endonasal approaches to the anterior cranial base.^{97,98} Benign and malignant tumors that traditionally required open craniofacial resections are being removed at some institutions without external incisions. The use of endoscopes also has allowed for the development of minimally invasive approaches to thyroid and parathyroid surgery.^{99–101} Minimally invasive techniques that aim to cure patient disease while limiting the side effects of surgery may shorten hospitalizations and recovery periods and enhance quality of life.

Nonsurgical Treatment

Nonsurgical therapy, in the forms of RT and chemotherapy, can be used independently and in conjunction with surgery in HNSCC management. Many combinations have been investigated over the past 60 years. In the past 2 decades, randomized controlled trials with a focus on multimodality approaches have resulted in an evolution of both surgical and nonsurgical treatment of HNSCC. Recently, targeted therapies against specific cellular receptors and signaling molecules have emerged and likely will play a large role in the future management of HNSCC.

Radiation therapy

Before 1948, the administration RT was limited to orthovoltage generators and radium implants. Orthovoltage radiation was characterized by poor depth distribution with limited efficacy against deeper tumors and a high degree of skin damage. At that time, poor cure rates and complications led to a gradual trend toward surgery for the treatment of most head and neck cancers.¹⁰² In the 1950s, however, the era of modern RT began with the advent of the linear accelerator and telecobalt units, which generated supervoltage radiation.¹⁰³ Supervoltage radiation, with its vastly improved depth distribution, allowed for the treatment of deeper tumors while sparing the skin. This advancement allowed radiation to maintain a prominent role in the treatment of HNSCC.

Definitive radiation therapy—RT has been used as primary treatment in all subsites of head and neck cancer, and its role compared with surgery has been evaluated continually.^{102,104,105} Earlier diagnosis and advances in RT accounted for a dramatic improvement in the cure rates of patients who were treated with irradiation during the second half of the 20th century. By 1984, a report in *Cancer* indicated that patients with early glottic cancer had a 5-year recurrence-free rate of 89% and an overall survival rate of 97%, and the vast majority of those patients had received RT.¹⁰⁶ This was improved compared with a 1968 publication, which reported a 5-year cumulative survival rate of 81% with RT.¹⁰⁵ RT as single-modality treatment remains an important option for early HNSCC and has produced high cure rates that are comparable to those produced with surgical treatment.¹⁰⁷ Thus, as arguments for END evolved, so did the rationale for elective irradiation of the clinically negative neck in patients at risk for occult metastases.^{108,109} Usually, elective treatment of the neck corresponds to the chosen treatment of the primary tumor. Finally, RT is used

frequently in early-stage oropharyngeal and hypopharyngeal carcinomas, because it has a cure rate comparable to that achieved by surgery but with lower morbidity.^{110,111}

Preoperative radiation therapy—Initially, the combination of RT and surgery for more advanced HNSCC was investigated in an effort to decrease recurrence rates in more advanced-stage cancers. The strengths of surgery for eliminating bulky disease and RT for eradicating subclinical foci of cancer were a logical combination.¹¹² In 1966, the first randomized clinical trial to address this issue was published in *Cancer*. Strong and colleagues demonstrated that patients who received low-dosage preoperative RT to the neck had a reduction in the incidence of cervical recurrence.¹¹³ After direct comparison in clinical trials, preoperative RT was replaced by postoperative (adjuvant) RT.^{114,115}

Adjuvant radiation therapy—The first randomized study to address preoperative versus postoperative RT in HNSCC was published in *Cancer* in 1977. Vandenbrouk and colleagues investigated the use of RT in combination with surgery for patients with hypopharyngeal cancers.¹¹⁶ They demonstrated that patients who underwent surgery and received adjuvant RT had a 56% 5-year survival rate compared with a 20% 5-year survival rate in the preoperative RT group. A phase 3 study performed by the Radiation Therapy Oncology Group (RTOG) demonstrated that locoregional control was significantly better with adjuvant RT compared with preoperative RT for HNSCC.^{114,115} In addition, high-risk pathologic prognostic factors, including multiple positive lymph nodes and ECS, were recognized in neck specimens.⁵⁵ Adjuvant RT became indicated for multiple positive lymph nodes and ECS based on these findings and on the increasing success with the technique.¹¹² Increased total dose to at least 63 Gy improves locoregional control when ECS is present.¹¹⁰ A *Cancer* review of 8795 patients in the Surveillance, Epidemiology, and End Results (SEER) database published this year demonstrated a 10% absolute increase in 5-year cancer-specific survival and overall survival for patients with lymph node-positive HNSCC who were treated with RT.¹¹⁷ More recently, chemotherapy has been added to RT in the adjuvant setting with increased locoregional control and disease-free survival in randomized controlled trials compared with RT alone.^{118,119} This is discussed below (see Adjuvant chemoradiation).

Salvage and palliative radiation therapy—Recurrent HNSCC is a difficult problem with a poor prognosis. Traditionally, surgery has been used for salvage after any definitive modality has failed if resection is possible. Radiation with or without chemotherapy can be used in patients who have not received RT in the past. Patients who have been irradiated previously and have unresectable recurrent disease pose a more difficult challenge; for these patients, palliative chemotherapy is the standard treatment option.¹²⁰ However, a recent *Cancer* study suggests that postoperative reirradiation is feasible for patients who undergo surgery for recurrent or second primary HNSCC.¹²¹ A recent prospective phase 2 trial suggests that reirradiation with chemotherapy may be offered in this setting with acceptable toxicities as well.¹²² Survival rates remain very poor. In patients with distant metastatic disease, cure rates are extremely low. Palliation in this setting is achieved with chemotherapy and supportive care.¹²⁰

Brachytherapy and intraoperative radiation therapy—Interstitial RT, or brachytherapy, has been described for many oral cavity and oropharyngeal cancers as well as for lymph node disease.¹²³ Brachytherapy allows for an increase in the concentration of radiation at the implant site while minimizing effects on normal surrounding tissue and has been shown to provide benefit in patients with previously irradiated, unresectable, recurrent disease at the primary site or in the neck.^{124,125} A recent *Cancer* study suggests a role for brachytherapy together with surgery for recurrent HNSCC in the neck.¹²⁶ Twenty-two patients underwent the placement of brachytherapy catheters at the time of salvage neck dissection, which resulted in regional control and survival rates that were improved from published historic controls. Direct intraoperative administration of radiation to the open operative site after surgical resection is another method that has been shown to be feasible in advanced and recurrent HNSCC.¹²⁷ Both approaches for administering higher doses of radiation to the tumor bed are under further investigation.

Altered fractionation radiation therapy—Over the past 2 decades, efforts to improve patient outcomes have been sought through the intensification of RT delivery. In 1985, a biologic basis for alteration of conventional fractionation schemes based on tissue responses to radiation was reported in *Cancer*.¹²⁸ Hyperfractionation and accelerated fractionation were potential means to increase the therapeutic gains of RT. Hyperfractionation was defined as dividing the treatment into smaller than conventional doses per fraction without changing overall treatment duration to increase the therapeutic differential between late-responding normal tissues and tumor. Accelerated fractionation was defined as shortening the overall treatment duration of a regimen using conventional dose fractions with a goal to minimize tumor growth during treatment. Two studies using twice-a-day fractionation schemes in HNSCC demonstrated acceptable patient tolerance^{129,130} and improved local control for advanced tumors.¹³⁰ A meta-analysis of patients receiving RT for HNSCC suggested that tumors underwent rapid repopulation beginning 4 weeks after the initiation of treatment, confirming that an increase in dose could compensate for this effect.^{131,132}

In 2006, the Meta-analysis of Radiotherapy in Carcinomas of Head and Neck (MARCH) Collaborative Group published a meta-analysis of 15 randomized trials addressing altered fractionation compared with conventional fractionation in definitive RT for HNSCC.¹³³ Altered fractionation demonstrated a statistically significant absolute survival benefit of 3.4% at 5 years with the highest benefit for hyperfractionated therapy (8% at 5 years). There was also a benefit of 6.4% at 5 years on locoregional control in favor of altered fractionation therapy. A recent phase 3 randomized controlled study comparing accelerated fractionated RT versus conventional RT in HNSCC demonstrated that, in the postoperative setting, there was no difference in 2-year locoregional control and overall survival.¹³⁴ The only scenario in which adjuvant accelerated fractionation trended toward improved control was in patients who had a delay in starting RT.

Highly conformal radiation therapy—Intensity-modulated RT (IMRT) is relatively new technology that was designed to increase the conformity of the radiation dose in an effort to minimize toxicity to normal tissues. Traditional 3-dimensional conformal RT uses computed tomography (CT) images to design volumetric portals and the resulting radiation

dose distribution.¹³⁵ Typically, 3 RT portals are used in this technique to create a very basic shape for the resulting dose distribution. Inverse planning is used in IMRT to define specific target doses for the tumor and maximum acceptable doses to surrounding normal tissue.^{135,136} On the basis of these values, a computer optimization algorithm determines beam parameters that will lead to the desired, volumetrically conformed dose distribution and allow for tumor dose escalation. In contrast to 3D conformal RT, IMRT uses a large number of radiation portals to achieve the tailored distribution. IMRT also allows for the delivery of a simultaneous, integrated boost without treatment field modifications. In addition, the use of 2-deoxy-2-(¹⁸F)fluoro-D-glucose-positron emission tomography/CT fusion for IMRT planning may further enhance the ability to maximize radiation dose to tumor while protecting normal structures.¹³⁷ In theory, the benefits of IMRT are attractive, and recent surveys published in *Cancer* indicate rapid and wide acceptance in clinical practice.^{138,139} Most of the current data are focused on nasopharyngeal cancer (NPC) and oropharyngeal cancer at single institutions, but these studies have demonstrated excellent locoregional control.^{135,136}

Stereotactic radiosurgery (SRS) is a form of highly conformal RT that allows the delivery of large doses of radiation to the tumor in a small number of fractions. The first description of SRS use in HNSCC was reported in *Cancer* for the palliation of skull base recurrences.¹⁴⁰ Recently, renewed interest in the treatment of recurrent HNSCC has been described.^{141,142} Early experience suggests it is an efficient, effective, and well tolerated means of providing treatment and palliation in this high-risk population.^{141,142}

Chemotherapy

During the first half of this journal's existence, chemotherapy had little significance in the treatment of HNSCC. Chemotherapy often was reserved for the palliative setting, in which advanced disease and prior therapy were associated with a poor outcome.¹⁴³ Early experimentation in mice included topical chemotherapy¹⁴⁴ after studies published in *Cancer* were the first to report a high rate of malignant cells in washings from operative wounds in the head and neck.^{145,146} In 1959, Sullivan et al introduced an innovative approach of continuous intra-arterial infusion of the antimetabolite methotrexate while delivering the metabolite citrovorum systemically to prevent systemic toxicities.¹⁴⁷ An early study demonstrated potential usefulness of intra-arterial chemotherapy in the palliative setting.^{148,149} Although the short-term response with intra-arterial chemotherapy usually was excellent, it seldom was sustained. Given the lack of a durable response and a high complication rate, the technique eventually was abandoned as a definitive treatment.¹⁵⁰ With the introduction of cisplatin as an antineoplastic agent, further investigation of chemotherapy in the treatment of head and neck cancer flourished in the 1970s; since that time, chemotherapy had been investigated in both the induction and adjuvant settings as well as concomitantly with RT.¹⁵¹ During that time, chemotherapy evolved from a role in palliation to an essential component in curative multimodality programs for locally advanced HNSCC.¹⁵²

Induction chemotherapy—Induction, or neoadjuvant, therapy, refers to a modality used before definitive therapy with the goal of maximizing the success of the definitive therapy.

Response to induction therapy also may be used in determining prognosis and selecting the definitive course of treatment. One of the earliest trials that investigated survival in an induction chemotherapy regimen was reported in *Cancer*.¹⁵³ That study compared patients who received 5-fluorouracil (5-FU) intra-arterially before RT with patients who received RT alone. Chemotherapy resulted in good tumor regression but did not result in an increase in survival. In the 1980s, multiple pilot studies featured cisplatin in combination with other chemotherapeutic agents in the neoadjuvant setting.^{154–160} These nonrandomized studies reported high response rates with tolerable toxicities, but they could not address survival. The first randomized trial to investigate the effect of induction chemotherapy in HNSCC was published in *Cancer* in 1987.¹⁶¹ That study demonstrated minimal toxicity but lower response to induction compared with preliminary studies. There was no effect on survival. One year later, a randomized trial by the Southwest Oncology Group (SWOG) was reported.¹⁶² That study produced response rates consistent with the preliminary trials but still did not demonstrate a survival benefit.

Despite the lack of survival benefit in the randomized trials, a significant finding in the preliminary studies identified a potentially valuable role for induction chemotherapy. Several studies demonstrated that response to initial chemotherapy predicted response to further treatment and that responders had significantly greater survival than nonresponders.^{154,158,159} This concept was cited in the design of the Veterans Affairs Laryngeal Cancer Study Group trial.¹⁶³ In that landmark study, which investigated nonsurgical laryngeal preservation, induction chemotherapy followed by RT was compared with surgery (laryngectomy) followed by RT in patients with advanced laryngeal cancer. In the induction arm, patients initially received 2 cycles of chemotherapy before they were assessed for response. Responders completed the organ-preservation protocol, and nonresponders underwent laryngectomy. A similarly designed study by the European Organization for Research and Treatment of Cancer (EORTC) in patients with hypopharyngeal cancer soon followed.¹⁶⁴ In both of those randomized trials, induction chemotherapy followed by RT in responders offered survival rates comparable to what was achieved with laryngectomy followed by RT.^{163,164} RTOG 91–11 was a follow-up randomized trial that evaluated optimal nonsurgical treatment of patients with locally advanced laryngeal cancer using laryngectomy-free survival as the primary endpoint.¹⁶⁵ No overall survival difference was evident between the 3 arms (induction cisplatin plus 5-FU followed by RT, RT with concurrent cisplatin, or RT alone), which may have been attributed to the effect of salvage laryngectomy.¹⁶⁶ Laryngectomy-free survival and locoregional control were highest in the patients who received concomitant chemotherapy and RT.¹⁶⁵

Although HNSCC is highly responsive to cisplatin-based induction chemotherapy (80%–90%), multiple phase 3 trials comparing induction chemotherapy followed by locoregional treatment with locoregional treatment alone have had mixed results with regard to decreasing distant metastasis and improving patient survival.^{167–169} A meta-analysis of induction chemotherapy resulted in a nonsignificant survival improvement of 2% at 5 years (hazard ratio [HR], 0.95; 95% confidence interval [CI], 0.88–1.01; $P = .10$).¹⁶⁹ However, there was a significant benefit from cisplatin plus 5-FU compared with the other induction regimens (HR, 0.88; 95% CI, 0.79–0.97). Interest in induction chemotherapy has continued

with the introduction of more active regimens that contain taxane. Three phase 3 clinical trials have demonstrated the potential for improved survival when a taxane is added to cisplatin plus 5-FU induction chemotherapy followed by RT or concurrent chemotherapy and RT (chemoradiotherapy [CRT]).^{170–172} Those studies did not include direct comparisons of induction strategies with concurrent CRT alone. Two additional phase 3 trials, Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) and Paradigm, currently are underway and may help determine whether docetaxel-containing induction chemotherapy will confer benefit beyond concurrent CRT without induction.^{173,174}

Adjuvant chemotherapy—On the basis of their findings of the poor prognostic value of ECS in the 1980s, Johnson and colleagues at the University of Pittsburgh began to offer adjuvant chemotherapy to patients with that pathologic finding.⁵⁸ High-risk patients received postoperative RT and a subsequent chemotherapy regimen for 6 months. The results of that nonrandomized study indicated a survival benefit from adjuvant chemotherapy but also noted poor patient compliance with the regimen. A randomized controlled trial of postoperative chemotherapy followed by RT compared with postoperative RT alone, however, demonstrated no survival benefit from the addition of chemotherapy.¹⁷⁵ With the success of concurrent CRT, the role for sequential application of adjuvant chemotherapy was diminished.

Salvage and palliative chemotherapy—Approximately half of patients with locally advanced HNSCC develop locoregional or distant recurrences. Chemotherapy is the standard-of-care treatment option for patients with recurrent or metastatic HNSCC with a focus on palliation and prolonging survival. Bleomycin, taxanes, carboplatin, methotrexate, and 5-FU are active in recurrent HNSCC and produce response rates from 10% to 40%.¹⁷⁶ Cisplatin and 5-FU typically serve as a standard chemotherapy regimen in patients with recurrent or metastatic HNSCC. Two-drug combinations may improve response rates, but not overall survival. Salvage surgery potentially is curative for a few patients with resectable locoregional recurrence.^{166,177} Reirradiation combined with chemotherapy after salvage surgery improved progression-free survival, but not overall survival.¹⁷⁸ Overall, the prognosis is poor for patients with recurrent or metastatic HNSCC.

Concurrent chemotherapy and radiation therapy

The combination of surgery, RT, and chemotherapy has been critical for the curative management of locally advanced HNSCC. Concurrent administration of chemotherapy and RT has a significant preclinical and clinical rationale and represents a significant therapeutic advance.¹⁷⁹ The concept of combining chemotherapy and radiation was discussed in *Cancer* as early as 1960.¹⁸⁰ Chemotherapy improves efficacy through its radiosensitizing ability in locoregional disease and by providing systemic therapy against distant metastatic disease.¹⁸¹ Today, concurrent regimens are standard treatment in the definitive setting of locally advanced disease and in the postoperative setting for high-risk pathology. This advance reflects not only an improvement in the biologic treatment of HNSCC but also demonstrates the successful development of a truly multidisciplinary approach to head and neck cancer care.

Definitive concurrent chemoradiation—With no clear advantage of induction or sequential adjuvant chemotherapy in randomized trials, the role of concurrently delivered CRT was studied intensively in the 1990s.¹⁸² Some of the earliest feasibility studies that addressed concurrent cisplatin-based CRT for locally advanced disease were published in *Cancer* in 1987.^{183,184} The trials concluded that the approach was effective and safe and justified a randomized controlled trial comparing CRT with RT alone.^{183–185} A randomized controlled trial published in 1997 demonstrated that concurrent CRT in patients with advanced locoregional, but resectable, HNSCC resulted in improved recurrence-free survival, decreased distant metastases, and increased primary site preservation compared to RT alone.¹⁸⁶ Treatment toxicity was increased but was deemed tolerable.

The Meta-Analysis of Chemotherapy on Head and Neck Cancer (MACH-NC) was designed to evaluate the effectiveness of different chemotherapy timing methods in the management of HNSCC.¹⁶⁹ That meta-analysis of 63 trials, which included nearly 11,000 patients with cancer of the oral cavity, oropharynx, larynx and hypopharynx, demonstrated that the addition of chemotherapy to locoregional treatment conferred an absolute survival benefit of 4% at 5 years (HR, 0.90; 95% CI, 0.85–0.94; $P < .0001$); the benefit that was confined to CRT (HR, 0.81; 95% CI, 0.76–0.88; $P < .0001$) resulted in an absolute survival benefit of 8% at 5 years.¹⁶⁶ An updated meta-analysis that included 24 additional studies confirmed these findings.^{169,187} The Meta-Analysis of Chemotherapy in Nasopharyngeal Carcinoma (MAC-NPC) also demonstrated a survival advantage from chemotherapy that was most apparent in the concurrent treatment group.¹⁸⁸

In 1998, the phase 2 randomized Intergroup 0099 Study demonstrated a significant survival advantage (67% vs 37%) with the use of concomitant cisplatin and RT followed by adjuvant cisplatin and 5-FU for advanced-stage NPC compared with RT alone.¹⁸⁹ A randomized trial that addressed stage III and IV oropharyngeal cancer demonstrated that concurrent CRT significantly improved the 3-year survival rate (51% vs 31%) compared with RT alone.¹⁹⁰ In 2003, RTOG 91–11 was published as a follow-up to the Veterans Affairs Laryngeal Cancer Study Group trial.¹⁶⁵ All 3 treatment arms, as described above (see Induction chemotherapy), were similar in terms of survival. However, concurrent CRT was significantly superior to induction chemotherapy followed by RT and RT alone with regard to laryngectomy-free survival and locoregional control. The findings of these reports have resulted in a markedly increased role of concurrent CRT in the definitive treatment of HNSCC.

Adjuvant concurrent chemoradiation—Because sequential adjuvant chemotherapy had a disappointing impact on overall survival and definitive concurrent CRT regimens were demonstrating promise and tolerability, concurrent CRT was applied in the postoperative setting for high-risk patients.¹⁵¹ These efforts culminated in 2 phase 3 trials that compared postoperative RT with or without concurrent cisplatin-based chemotherapy in patients with high-risk, resected HNSCC.^{118,119} The first study was conducted by the RTOG and was supported by the Eastern Cooperative Oncology Group (ECOG) and the SWOG.¹¹⁹ The second study was performed by the EORTC.¹¹⁸ Both studies used the same cisplatin schedule (100 mg/m² on Days 1, 22, and 43 during RT). Inclusion criteria and high-risk factors were similar. High-risk pathologic features included multiple lymph node

involvement, ECS, and positive surgical margins. Both studies demonstrated that the addition of cisplatin-based chemotherapy improved locoregional control and disease-free survival. The EORTC study showed a significant improvement in overall survival for the concurrent CRT group, whereas the RTOG showed a trend in that direction. There was no effect on distant metastasis control in either trial, whereas the incidence of acute adverse effects was greater with chemotherapy in both studies.

In an attempt to identify the patients who would most benefit from such intense treatment, the authors of both studies collaborated to perform a comparative analysis of the 2 trials.¹⁹¹ The goal was to define the most significant high-risk indicators that would improve direction of the escalated treatment regimen. ECS and microscopically involved surgical margins were identified as the most significant prognostic factors for a poor outcome. Accordingly, the authors recommended the addition of concomitant chemotherapy to postoperative RT in patients with either or both of these findings who were fit medically to tolerate the added modality. Other risk factors, such as stage III/IV disease, perineural invasion, vascular tumor embolism, and clinically enlarged level IV/V lymph nodes secondary to oral cavity or oropharyngeal primaries, which traditionally were considered high-risk features, showed nonsignificant trends in favor of postoperative concurrent CRT. It is noteworthy that patients who had 2 or more histopathologically involved lymph nodes without ECS as their only risk factor did not seem to benefit from the addition of chemotherapy in the analysis.

Targeted therapeutics and novel agents

Within the last 2 decades, our understanding of the molecular mechanisms underlying HNSCC disease progression and advances in molecular biology have led to the development of targeted therapeutic agents. The best example of targeted therapy development is imatinib for the treatment of chronic myeloid leukemia (CML).¹⁹² CML is caused by a chromosomal translocation, resulting in the formation of the constitutively activated fusion tyrosine kinase BCR-ABL. Imatinib was identified as a small-molecule antagonist of BCR-ABL and was approved by the US Food and Drug Administration in 2002 as first-line treatment for CML. Imatinib has dramatically altered the treatment of CML patients and has become a vastly superior treatment compared with any available alternatives.

Although there has not been a success story as dramatic as imatinib for HNSCC treatment, several targeted therapeutic agents are being pursued. The epidermal growth factor receptor (EGFR) is a member of the ErbB growth factor receptor tyrosine kinase family.¹⁹³ EGFR commonly is overexpressed in HNSCC. Increased expression of EGFR and the ligand, transforming growth factor- α (TGF- α), have been associated with disease recurrence and worse patient survival.^{194,195} EGFR-dependent signaling pathways are activated in HNSCC, leading to disease progression through tumor cell proliferation and antiapoptosis. Within several similar tumors, including colorectal cancer, nonsmall cell lung cancer, and HNSCC, Mendelsohn and colleagues have proposed that EGFR blockade inhibits tumor growth.^{196,197}

Several strategies have been developed to target EGFR, including antibodies that target the extracellular ligand-binding region of EGFR and small-molecule inhibitors of the intracellular tyrosine kinase domain of EGFR (tyrosine kinase inhibitors). Cetuximab, an

immunoglobulin-G1 chimeric monoclonal antibody directed against EGFR, was the first molecularly targeted agent to result in improved survival in patients with HNSCC. In combination with RT, cetuximab demonstrated improved locoregional control (HR, 0.68; 95% CI, 0.52–0.89; $P = .005$; 3 years, 47% vs 34%), progression-free survival (3-years, 42% vs 31%; $P = .04$), and overall survival (3-years, 55% vs 45%; $P = .05$) compared with RT alone.¹⁹⁸ RT plus cetuximab is an alternative to CRT that should be considered strongly in patients who cannot tolerate chemotherapy, because this regimen is not associated with increased myelosuppression or mucositis. However, no randomized trials have been completed comparing RT-cetuximab versus platinum-based concurrent CRT. In addition, ongoing studies are focused on the incorporation of EGFR inhibitors into various CRT regimens. A recent phase 2 study evaluated the combination of cetuximab with cisplatin and accelerated boost RT with promising preliminary efficacy, although there were concerns regarding enhanced toxicity.¹⁹⁹

Other novel agents currently are under active investigation. These include other EGFR antibodies, such as the fully human panitumumab, which has demonstrated significant single-agent activity in colorectal cancer with increased progression-free survival.²⁰⁰ In addition, the EGFR tyrosine kinase inhibitor erlotinib has demonstrated modest single-agent activity in recurrent or metastatic HNSCC and currently is being evaluated in combination with standard CRT regimens.^{201,202} Activation of the Src kinase family is important in HNSCC progression.²⁰³ Dasatinib is an oral agent with activity against Src kinase family members, and clinical trials in HNSCC currently are under development. Finally, angiogenesis is the formation of new blood vessels, which are required to supply oxygen and nutrients as a tumor rapidly grows. Of the many factors that influence angiogenesis, vascular endothelial growth factor (VEGF) and its receptors are the most important.²⁰⁴ Bevacizumab, a monoclonal antibody against VEGF, currently is being evaluated in combination with concurrent CRT or erlotinib in HNSCC patients. In addition, vanitinib has become an interesting candidate agent given its ability to competitively inhibit EGFR and VEGF receptor 2 (VEGFR2). The combination of these agents with conventional CRT may be a promising strategy for novel and potentially more efficacious treatments for patients with HNSCC patients as more targeted therapeutic agents are developed.

Summary of Current Treatments and Future Directions

Caring for patients with head and neck cancer is complex and requires the expertise of many specialists, including the head and neck surgeon, radiation oncologist, medical oncologist, plastic/reconstructive surgeon, radiologist, pathologist, dental prosthodontist, nurse, nutritionist, and speech/swallow therapist. Within each of these fields, subspecialty dedication to head and neck cancer has allowed for marked improvement in patient care. More importantly, cooperation across these fields has created an integrated multidisciplinary approach that maximizes patient outcomes and facilitates the development of better treatment regimens.

In patients with early-stage HNSCC, single-modality treatment with surgery or RT remains the therapy of choice. Factors like the patient's performance status, the expected degree of functional impairment with surgery, and patient and physician preferences guide the

decision between RT and surgery.²⁰⁵ For T1/T2 laryngeal cancer, RT long has been considered equivalent to surgery in terms of survival outcomes.^{206,207} Guidelines for the use of larynx-preservation strategies in the treatment of laryngeal cancer were published in 2006.²⁰⁷ Management options for early tumors include endoscopic resection and RT. The decision to use RT versus endoscopic resection is influenced by tumor location and expertise available at a specific treatment center.^{208,209} Similarly, RT is an option in early-stage oral cavity cancer as either external beam or brachytherapy; however, in this setting, RT is limited by xerostomia, mucositis, and osteoradionecrosis.^{210,211} Surgery has the advantage of shorter treatment time and minimal morbidity for small tumors with RT available as a treatment option in the event that a second primary tumor arises. NPC and some oropharyngeal carcinomas are treated primarily with RT for early-stage tumors because of their radiosensitivity and the relative increased morbidity of surgical resection in these anatomic regions.

HNSCC that presents with a cervical metastasis from an unknown primary site represents a unique situation given its inherently high stage despite an occult primary tumor. Although the standard treatment for cervical metastases with unknown primary is neck dissection followed by RT, a study in *Cancer* suggested these patients would benefit from treatment with CRT, which is being used increasingly.^{212,213} The favorable treatment response to CRT is understandable, because it is believed that most cervical metastases originate in the oropharynx. A meta-analysis reported in *Cancer* demonstrated that positron emission tomography/CT imaging enhances the ability to identify the primary site beyond the traditional panendoscopy with directed biopsies, thus allowing more directed treatment.²¹⁴

In patients with resectable, locally advanced HNSCC, surgery followed by postoperative CRT or CRT alone may be the primary therapy chosen. Oral cavity primary lesions usually are treated with surgery, because the cosmetic and functional results are considered satisfactory, and experience with primary CRT has been less extensive. Locally advanced oropharyngeal primaries usually are treated with CRT, which produces good efficacy and functional results.²¹⁵ Patients with locally advanced hypopharyngeal and laryngeal primaries should be considered for organ-preservation approaches.²⁰⁷ Although organ preservation is an important goal, such treatments must preserve both anatomy and function. The current standard of care of NPC (stage IIB or higher) is concurrent cisplatin and RT followed by adjuvant cisplatin and 5-FU according to the protocol of the Intergroup 0099 study.^{189,213} In patients with unresectable, locally advanced HNSCC, CRT is standard unless the addition of chemotherapy is not indicated because of poor performance status or comorbid illnesses.²¹⁶

Clinical trial data have provided a range of potential combinations for CRT regimens. Although an in-depth discussion of different chemotherapeutic agents and combinations is beyond the scope of this review, meta-analyses shed some light on this decision process. Borman and colleagues performed a pooled analysis of 18 randomized controlled trials of concurrent CRT.²¹⁷ They demonstrated that platinum-based CRT, especially platinum with 5-FU, was associated with a significant survival benefit compared with conventional RT alone. Current standard chemotherapy-containing regimens for HNSCC include cisplatin or carboplatin with or without 5-FU based on the treatment defined in randomized controlled

trials.^{118,119,163–165,189,190,218} However, the addition of a taxane to cisplatin and 5-FU induction chemotherapy led to improved results, which support the addition of taxane in induction regimens.^{170–172} The DeCIDE trial and the Paradigm study will help to define the role of taxane-based induction chemotherapy and concurrent CRT regimens.^{173,174}

Budach and colleagues performed a meta-analysis to define the role of altered fractionation RT in concurrent CRT regimens.²¹⁹ They discovered that concurrent CRT using 5-FU, cisplatin, carboplatin, and mitomycin C as single agents or combinations of 5-FU with any of the other drugs resulted in a large survival advantage regardless of the RT schedule. Only when RT was used alone did hyperfractionation lead to a significant improvement in overall survival, whereas accelerated fractionation alone did not increase overall survival. Several multi-institutional randomized trials investigating IMRT also are in progress, including 2 RTOG studies: 1 investigating IMRT versus conventional RT in early-stage oropharyngeal cancer and another examining IMRT with and without chemotherapy in NPC.^{135,136} The Groupe d'Oncologie Radiothérapie Tête et Cou (GORTEC) is evaluating IMRT with concomitant cisplatin versus conventional RT and cisplatin in patients with stage III and IV HNSCC.¹³⁵ That study is designed to assess the efficacy as well as the potential for decreased toxicity with IMRT. RTOG 0522 is designed to define the effect of cetuximab added to concurrent CRT by comparing concurrent cisplatin and accelerated RT with and without cetuximab.²²⁰

It is important to reflect on the results of the past as we look to the future for continued improvements in HNSCC care. In 2000, Ries and colleagues published a report in *Cancer* on the status of cancer within the United States and indicated that oral cavity/pharyngeal cancer had one of the highest decreases in death rate of all cancer sites over the previous decade.²²¹ Unfortunately, the opposite may be true for laryngeal cancer. The MACH-NC demonstrated that there was a nonsignificant increase in death for laryngeal preservation protocols compared with surgery followed by RT.¹⁶⁹ In 2006, an analysis of the National Cancer Data Base (NCDB) confirmed that laryngeal cancer was the only cancer type that trended toward decreased survival when the 1990s were compared with the 1980s.²²² More recently, an analysis of the NCDB that specifically examined advanced-stage laryngeal cancer from 1995 through 1998 showed increased survival for total laryngectomy compared with chemotherapy plus RT or RT alone, suggesting that clinical practice outcomes may differ from those of structured randomized trials.²²³ Although this dataset predated RTOG Study 91–11, vigilance must be maintained regarding the applicability of randomized controlled clinical trial regimens to wider clinical practice. Careful evaluation of the potential effects on survival as well as the likelihood of retained function must precede the use of organ-preservation regimens for advanced-stage laryngeal cancer. Just as resection of a structure that can be cured oncologically and preserved functionally with nonsurgical treatment does not seem reasonable, resistance to excision of resectable tumors that are likely to have poor residual function after organ-preservation CRT regimens is similarly problematic. This is especially true in the latter instance if the nonsurgical approach has the potential to result in decreased survival or increased morbidity. List and colleagues demonstrated that the top pre-treatment priority by far for patients with HNSCC was achieving a cure.²²⁴ Better pretreatment selection criteria, such as responsiveness to

induction chemotherapy or molecular markers, may facilitate the selection of optimal treatment modalities in the future. Inclusion of patients in clinical trials not only is encouraged but is necessary for continued advancement of the field.

Conclusions

In the inaugural year of *Cancer*, Karnofsky et al published the Karnofsky performance status scale as a means to quantify the activity levels of patients as affected by their disease.²²⁵ This scale still is used widely to describe the functional status of patients and to define eligibility for clinical trials (Fig. 4). Despite the continued application of the Karnofsky performance status scale, much has changed in the knowledge and treatment of cancer since 1948. In the earliest issues of *Cancer*, the ‘Current Cancer Literature’ section grouped oral cavity cancer with cancers of the stomach, liver, pancreas, and anus. Specialists dedicated exclusively to the treatment of head and neck cancer were nonexistent. Radiation often was delivered by dermatologists, and surgeons and oncologists had limited roles in the management of head and neck cancer. Today, each issue of *Cancer* dedicates an entire section to head and neck cancer, reflecting the consolidation and advancement of this field.

The development of novel chemotherapy regimens and targeted therapeutic agents potentially may improve locoregional control and overall patient survival. Large cooperative groups, like the RTOG, ECOG, SWOG, and EORTC, facilitate patient recruitment into multiinstitutional prospective randomized trials, which have provided us with the necessary data to define current and future standards of care. Efforts to identify biomarkers that predict disease behavior will continue as individualized therapy evolves. Validated quality-of-life measures further define treatment outcomes,^{226,227} and intensification of combined treatment likely will require significant attention regarding treatment-induced toxicities. The use of tobacco-related products remains significant globally, but additional etiologic factors such as HPV also affect HNSCC presentation, behavior, and treatment. Although progress has been made during the past 60 years, a great deal remains to be accomplished.

Acknowledgments

The authors thank Jonas T. Johnson and Rohan Walvekar for their critical review of the article and Penny Oliver for the medical illustration shown in Figure 2.

References

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin.* 2005; 55:74–108. [PubMed: 15761078]
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. *CA Cancer J Clin.* 2007; 57:43–66. [PubMed: 17237035]
3. Ries, LAG.; Melbert, D.; Krapcho, M., et al. E. SEER Cancer Statistics Review, 1975–2004. National Cancer Institute; Available from: http://seer.cancer.gov/csr/1975_2004/ [Accessed on August 12, 2008]
4. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the US population ages 20–44 years. *Cancer.* 2005; 103:1843–1849. [PubMed: 15772957]
5. Levin M. Some epidemiological features of cancer. *Cancer.* 1948; 1:489–497. [PubMed: 18887918]

6. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. *Cancer*. 1953; 6:963–968. [PubMed: 13094644]
7. The Surgeon General's Advisory Committee on Smoking and Health. Public Health Service Publication No. 1103. Washington, DC: Department of Health Education, and Welfare, Public Health Service; 1964. Smoking and Health: Report of the Advisory Committee to the Surgeon General of Public Health Service.
8. Watson WL, Conte AJ. Smoking and lung cancer. *Cancer*. 1954; 7:245–249. [PubMed: 13141215]
9. Samji HA, Jackler RK. "Not one single case of throat irritation": misuse of the image of the otolaryngologist in cigarette advertising. *Laryngoscope*. 2008; 118:415–427. [PubMed: 18197139]
10. Hoffmann D, Wynder EL. A study of tobacco carcinogenesis. XI. Tumor initiators, tumor accelerators, and tumor promoting activity of condensate fractions. *Cancer*. 1971; 27:848–864. [PubMed: 5574075]
11. Wynder EL, Gottlieb S, Wright G. A study of tobacco carcinogenesis. IV. Different tobacco types. *Cancer*. 1957; 10:1206–1209. [PubMed: 13489672]
12. Wynder EL, Hoffmann D. A study of tobacco carcinogenesis. VII. The role of higher polycyclic hydrocarbons. *Cancer*. 1959; 12:1079–1086. [PubMed: 13846285]
13. Wynder EL, Hoffmann D. A study of tobacco carcinogenesis. VIII. The role of the acidic fractions as promoters. *Cancer*. 1961; 14:1306–1315. [PubMed: 14008628]
14. Wynder EL, Hoffmann D. A study of tobacco carcinogenesis. X. Tumor promoting activity. *Cancer*. 1969; 24:289–301. [PubMed: 5802499]
15. Wynder EL, Kopf P, Ziegler H. A study of tobacco carcinogenesis. II. Dose-response studies. *Cancer*. 1957; 10:1193–1200. [PubMed: 13489670]
16. Wynder EL, Mann J. A study of tobacco carcinogenesis. III. Filtered cigarettes. *Cancer*. 1957; 10:1201–1205. [PubMed: 13489671]
17. Wynder EL, Taguchi KT, Baden V, Hoffmann D. Tobacco carcinogenesis. IX. Effect of cigarette smoke on respiratory tract of mice after passive inhalation. *Cancer*. 1968; 21:134–153. [PubMed: 4294525]
18. Wynder EL, Wright G. A study of tobacco carcinogenesis. I. The primary fractions. *Cancer*. 1957; 10:255–271. [PubMed: 13426984]
19. Wynder EL, Wright G, Lam J. A study of tobacco carcinogenesis. V. The role of pyrolysis. *Cancer*. 1958; 11:1140–1148. [PubMed: 13608415]
20. Wynder EL, Wright GF, Lam J. A study of tobacco carcinogenesis. VI. The role of precursors. *Cancer*. 1959; 12:1073–1078. [PubMed: 13846291]
21. Wynder EL, Bross IJ. A study of etiological factors in cancer of the esophagus. *Cancer*. 1961; 14:389–413. [PubMed: 13786981]
22. Wynder EL, Bross IJ, Day E. A study of environmental factors in cancer of the larynx. *Cancer*. 1956; 9:86–110. [PubMed: 13284704]
23. Wynder EL, Bross IJ, Feldman RM. A study of the etiological factors in cancer of the mouth. *Cancer*. 1957; 10:1300–1323. [PubMed: 13489682]
24. Wynder EL, Covey LS, Mabuchi K, Mushinski M. Environmental factors in cancer of the larynx: a second look. *Cancer*. 1976; 38:1591–1601. [PubMed: 991080]
25. Vogler WR, Lloyd JW, Milmore BK. A retrospective study of etiological factors in cancer of the mouth, pharynx, and larynx. *Cancer*. 1962; 15:246–258. [PubMed: 13926472]
26. Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking in relation to oral and pharyngeal cancer. *Cancer Res*. 1988; 48:3282–3287. [PubMed: 3365707]
27. Mashberg A, Boffetta P, Winkelmann R, Garfinkel L. Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among US veterans. *Cancer*. 1993; 72:1369–1375. [PubMed: 8339227]
28. Muscat JE, Wynder EL. Tobacco, alcohol, asbestos, and occupational risk factors for laryngeal cancer. *Cancer*. 1992; 69:2244–2251. [PubMed: 1562970]

29. Shindoh M, Chiba I, Yasuda M, et al. Detection of human papillomavirus DNA sequences in oral squamous cell carcinomas and their relation to p53 and proliferating cell nuclear antigen expression. *Cancer*. 1995; 76:1513–1521. [PubMed: 8635051]
30. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. *Cancer Epidemiol Biomarkers Prev*. 2005; 14:467–475. [PubMed: 15734974]
31. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. *Virus Res*. 2002; 89:213–228. [PubMed: 12445661]
32. Hobbs CG, Sterne JA, Bailey M, Heyderman RS, Birchall MA, Thomas SJ. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. *Clin Otolaryngol*. 2006; 31:259–266. [PubMed: 16911640]
33. Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. *Cancer*. 1997; 79:595–604. [PubMed: 9028373]
34. Mork J, Lie AK, Glatte E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. *N Engl J Med*. 2001; 344:1125–1131. [PubMed: 11297703]
35. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. *N Engl J Med*. 2007; 356:1944–1956. [PubMed: 17494927]
36. Schwartz SM, Daling JR, Doody DR, et al. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. *J Natl Cancer Inst*. 1998; 90:1626–1636. [PubMed: 9811312]
37. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. *J Clin Oncol*. 2006; 24:5630–5636. [PubMed: 17179101]
38. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. *Cancer*. 2001; 92:805–813. [PubMed: 11550151]
39. Martin H, Del Valle B, Ehrlich H, Cahan WG. Neck dissection. *Cancer*. 1951; 4:441–499. [PubMed: 14839606]
40. Crile G. Excision of cancer of the head and neck. With special reference to the plan of dissection based on 1 hundred and thirty-2 operations. *JAMA*. 1906; 47:1780–1786.
41. Ferlito A, Rinaldo A, Silver CE, et al. Neck dissection: then and now. *Auris Nasus Larynx*. 2006; 33:365–374. [PubMed: 16889923]
42. Martin H. The case for prophylactic neck dissection. *Cancer*. 1951; 4:92–97. [PubMed: 14801775]
43. Myers EN, Gastman BR. Neck dissection: an operation in evolution: Hayes Martin lecture. *Arch Otolaryngol Head Neck Surg*. 2003; 129:14–25. [PubMed: 12525190]
44. Suarez O. El problema de las metastasis linfaticas y alejadas del cancer de laringe e hypofaringe. *Rev Otorrinolaringol*. 1963; 23:83–99.
45. Bocca E. Supraglottic laryngectomy and functional neck dissection. *J Laryngol Otol*. 1966; 80:831–838. [PubMed: 5945238]
46. Bocca E, Pignataro O, Sasaki CT. Functional neck dissection. A description of operative technique. *Arch Otolaryngol*. 1980; 106:524–527. [PubMed: 7406757]
47. Bocca E, Pignataro O, Oldini C, Cappa C. Functional neck dissection: an evaluation and review of 843 cases. *Laryngoscope*. 1984; 94:942–945. [PubMed: 6738274]
48. Frazell EL, Lucas JC Jr. Cancer of the tongue. Report of the management of 1554 patients. *Cancer*. 1962; 15:1085–1099. [PubMed: 13959369]
49. Vandenbrouck C, Sancho-Garnier H, Chassagne D, Saravane D, Cachin Y, Micheau C. Elective versus therapeutic radical neck dissection in epidermoid carcinoma of the oral cavity: results of a randomized clinical trial. *Cancer*. 1980; 46:386–390. [PubMed: 6992980]
50. Lindberg R. Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. *Cancer*. 1972; 29:1446–1449. [PubMed: 5031238]
51. Shah JP. Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. *Am J Surg*. 1990; 160:405–409. [PubMed: 2221244]

52. Shah JP, Candela FC, Poddar AK. The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity. *Cancer*. 1990; 66:109–113. [PubMed: 2354399]
53. Johnson JT, Barnes EL, Myers EN, Schramm VL Jr, Borochoviz D, Sigler BA. The extracapsular spread of tumors in cervical node metastasis. *Arch Otolaryngol*. 1981; 107:725–729. [PubMed: 7316852]
54. Johnson JT, Myers EN, Bedetti CD, Barnes EL, Schramm VL Jr, Thearle PB. Cervical lymph node metastases. Incidence and implications of extracapsular carcinoma. *Arch Otolaryngol*. 1985; 111:534–537. [PubMed: 4026664]
55. Snow GB, Annys AA, van Slooten EA, Bartelink H, Hart AA. Prognostic factors of neck node metastasis. *Clin Otolaryngol Allied Sci*. 1982; 7:185–192. [PubMed: 7105450]
56. Snyderman NL, Johnson JT, Schramm VL Jr, Myers EN, Bedetti CD, Thearle P. Extracapsular spread of carcinoma in cervical lymph nodes. Impact upon survival in patients with carcinoma of the supraglottic larynx. *Cancer*. 1985; 56:1597–1599. [PubMed: 4027895]
57. Byers RM. Modified neck dissection. A study of 967 cases from 1970 to 1980. *Am J Surg*. 1985; 150:414–421. [PubMed: 4051103]
58. Johnson JT, Wagner RL, Myers EN. A long-term assessment of adjuvant chemotherapy on outcome of patients with extracapsular spread of cervical metastases from squamous carcinoma of the head and neck. *Cancer*. 1996; 77:181–185. [PubMed: 8630927]
59. Byers RM, Wolf PF, Ballantyne AJ. Rationale for elective modified neck dissection. *Head Neck Surg*. 1988; 10:160–167. [PubMed: 3235344]
60. Pitman KT, Johnson JT, Myers EN. Effectiveness of selective neck dissection for management of the clinically negative neck. *Arch Otolaryngol Head Neck Surg*. 1997; 123:917–922. [PubMed: 9305240]
61. Chepeha DB, Hoff PT, Taylor RJ, Bradford CR, Teknos TN, Esclamado RM. Selective neck dissection for the treatment of neck metastasis from squamous cell carcinoma of the head and neck. *Laryngoscope*. 2002; 112:434–438. [PubMed: 12148849]
62. Pellitteri PK, Robbins KT, Neuman T. Expanded application of selective neck dissection with regard to nodal status. *Head Neck*. 1997; 19:260–265. [PubMed: 9213103]
63. Simental AA Jr, Duvvuri U, Johnson JT, Myers EN. Selective neck dissection in patients with upper aerodigestive tract cancer with clinically positive nodal disease. *Ann Otol Rhinol Laryngol*. 2006; 115:846–849. [PubMed: 17165668]
64. Gould EA, Winship T, Philbin PH, Kerr HH. Observations on a “sentinel node” in cancer of the parotid. *Cancer*. 1960; 13:77–78. [PubMed: 13828575]
65. Shoaib T, Soutar DS, MacDonald DG, et al. The accuracy of head and neck carcinoma sentinel lymph node biopsy in the clinically N0 neck. *Cancer*. 2001; 91:2077–2083. [PubMed: 11391588]
66. Cote V, Kost K, Payne RJ, Hier MP. Sentinel lymph node biopsy in squamous cell carcinoma of the head and neck: where we stand now, and where we are going. *J Otolaryngol*. 2007; 36:344–349. [PubMed: 18076844]
67. Lombardi CP, Raffaelli M, Princi P, De Crea C, Bellantone R. Minimally invasive video-assisted functional lateral neck dissection for metastatic papillary thyroid carcinoma. *Am J Surg*. 2007; 193:114–118. [PubMed: 17188101]
68. Terris DJ, Monfared A, Thomas A, Kambham N, Saenz Y. Endoscopic selective neck dissection in a porcine model. *Arch Otolaryngol Head Neck Surg*. 2003; 129:613–617. [PubMed: 12810462]
69. Malloy KM, Cognetti DM, Wildmore BM, et al. Feasibility of endoscopic sentinel node biopsy in the porcine neck. *Otolaryngol Head Neck Surg*. 2007; 136:806–810. [PubMed: 17478220]
70. Pitman KT, Sisk JD. Endoscopic sentinel lymph node biopsy in a porcine model. *Laryngoscope*. 2006; 116:804–808. [PubMed: 16652092]
71. Morrison LF. Carcinoma of the larynx. I. Carcinoma of the laryngopharynx. *Laryngoscope*. 1952; 62:53–60. [PubMed: 14909546]
72. Pollack RS. Laryngectomy and radical neck dissection. *Cancer*. 1955; 8:1177–1184. [PubMed: 13270235]
73. Martin H. The incidence of total and partial laryngectomy, 1947 and 1952. *Cancer*. 1955; 8:1122–1125. [PubMed: 13270226]

74. Pressman JJ, Simon MB, Monell CM. Anatomic studies related to the dissemination of cancer of the larynx. *Cancer*. 1961; 14:1131–1138. [PubMed: 13737880]
75. Alonso J. Conservative surgery of the larynx. *Trans Am Acad Ophthalmol Otolaryngol*. 1947; 51:633–642. [PubMed: 20258270]
76. Majer EH, Rieder W. Technic of laryngectomy permitting the conservation of respiratory permeability (cricohyoidopexy). *Ann Otolaryngol Chir Cervicofac*. 1959; 76:677–681.
77. Weinstein, GS.; Laccourreye, O.; Brasnu, D.; Laccourreye, H. *Organ Preservation Surgery for Laryngeal Cancer*. San Diego, Calif: Singular Publishing Group; 2000.
78. MacComb WS. Cancer of the larynx. *Cancer*. 1966; 19:149–156. [PubMed: 5951994]
79. Ambrosch P. The role of laser microsurgery in the treatment of laryngeal cancer. *Curr Opin Otolaryngol Head Neck Surg*. 2007; 15:82–88. [PubMed: 17413407]
80. Genden EM, Ferlito A, Silver CE, et al. Evolution of the management of laryngeal cancer. *Oral Oncol*. 2007; 43:431–439. [PubMed: 17112771]
81. Solares CA, Strome M. Transoral robot-assisted CO2 laser supraglottic laryngectomy: experimental and clinical data. *Laryngoscope*. 2007; 117:817–820. [PubMed: 17473675]
82. Weinstein GS, O'Malley BW Jr, Snyder W, Hockstein NG. Transoral robotic surgery: supraglottic partial laryngectomy. *Ann Otol Rhinol Laryngol*. 2007; 116:19–23. [PubMed: 17305273]
83. Conley JJ. Free skin grafting in the sinus, oral, and pharyngeal areas in radical surgery of the head and neck. *Cancer*. 1954; 7:444–454. [PubMed: 13160933]
84. Edgerton MT Jr. Replacement of lining to oral cavity following surgery. *Cancer*. 1951; 4:110–119. [PubMed: 14801777]
85. Conway H, Murray JE. Indications for reconstruction at the time of surgical excision of cancer of the oral cavity. *Cancer*. 1953; 6:46–56. [PubMed: 13009651]
86. Walsh TS Jr. Buried metallic prosthesis for mandibular defects. *Cancer*. 1954; 7:1002–1009. [PubMed: 13199778]
87. Wilkins SA Jr. Immediate reconstruction of the cervical esophagus: a new method. *Cancer*. 1955; 8:1189–1197. [PubMed: 13270237]
88. Harrold CC Jr. The artificial pharyngeal pouch: another alternative in reconstruction after laryngectomy. *Cancer*. 1957; 10:928–932. [PubMed: 13472638]
89. Bakamjian VY. A two-stage method for pharyngoesophageal reconstruction with a primary pectoral skin flap. *Plast Reconstr Surg*. 1965; 36:173–184. [PubMed: 14339173]
90. McCraw JB, Dibbell DG, Carraway JH. Clinical definition of independent myocutaneous vascular territories. *Plast Reconstr Surg*. 1977; 60:341–352. [PubMed: 142995]
91. Ariyan S. The pectoralis major myocutaneous flap. A versatile flap for reconstruction in the head and neck. *Plast Reconstr Surg*. 1979; 63:73–81. [PubMed: 372988]
92. Soutar DS, Scheker LR, Tanner NS, McGregor IA. The radial forearm flap: a versatile method for intra-oral reconstruction. *Br J Plast Surg*. 1983; 36:1–8. [PubMed: 6821714]
93. Yang G. Forearm free skin flap transplantation. *Natl Med J China*. 1981; 61:139–141.
94. Gilbert A. Free transfer of the fibular shaft. *Int J Microsurg*. 1979; 1:100–105.
95. Urken ML. Composite free flaps in oromandibular reconstruction. Review of the literature. *Arch Otolaryngol Head Neck Surg*. 1991; 117:724–732. [PubMed: 1863437]
96. Smith RB, Snizek JC, Weed DT, Wax MK. Utilization of free tissue transfer in head and neck surgery. *Otolaryngol Head Neck Surg*. 2007; 137:182–191. [PubMed: 17666238]
97. Snyderman CH, Carrau RL, Kassam AB, et al. Endoscopic skull base surgery: principles of endonasal oncological surgery. *J Surg Oncol*. 2008; 97:658–664. [PubMed: 18493946]
98. Mehta RP, Cueva RA, Brown JD, et al. What's new in skull base medicine and surgery? Skull Base Committee Report. *Otolaryngol Head Neck Surg*. 2006; 135:620–630. [PubMed: 17011428]
99. Lai S, Walvekar R, Ferris R. Minimally invasive video-assisted thyroidectomy: expanded indications and oncologic completeness. *Head Neck*. In press.
100. Miccoli P, Berti P, Materazzi G, Donatini G. Minimally invasive video assisted parathyroidectomy (MIVAP). *Eur J Surg Oncol*. 2003; 29:188–190. [PubMed: 12633564]

101. Miccoli P, Materazzi G. Minimally invasive, video-assisted thyroidectomy (MIVAT). *Surg Clin North Am.* 2004; 84:735–741. [PubMed: 15145231]
102. Mead PH. Surgery or radiotherapy for tonsil cancer? *Cancer.* 1963; 16:195–198. [PubMed: 13934296]
103. Langlands AO. Radiation therapy in the treatment of cancer: the past, the present, and the future. *Aust N Z J Surg.* 1982; 52:331–335. [PubMed: 6956306]
104. Montana GS, Hellman S, Von Essen CF, Kligerman MM. Carcinoma of the tongue and floor of the mouth. Results of radical radiotherapy. *Cancer.* 1969; 23:1284–1289. [PubMed: 4977680]
105. Perez CA, Holtz S, Ogura JH, Dedo HH, Powers WE. Radiation therapy of early carcinoma of the true vocal cords. *Cancer.* 1968; 21:764–771. [PubMed: 5643768]
106. Kaplan MJ, Johns ME, Clark DA, Cantrell RW. Glottic carcinoma. The roles of surgery and irradiation. *Cancer.* 1984; 53:2641–2648. [PubMed: 6722722]
107. Fletcher GH, Jessee RH. The place of irradiation in the management of the primary lesion in head and neck cancers. *Cancer.* 1977; 39(2 suppl):862–867. [PubMed: 837349]
108. Fletcher GH. Elective irradiation of subclinical disease in cancers of the head and neck. *Cancer.* 1972; 29:1450–1454. [PubMed: 5031239]
109. Jesse RH, Fletcher GH. Treatment of the neck in patients with squamous cell carcinoma of the head and neck. *Cancer.* 1977; 39(2 suppl):868–872. [PubMed: 837350]
110. Mendenhall WM, Morris CG, Amdur RJ, et al. Definitive radiotherapy for tonsillar squamous cell carcinoma. *Am J Clin Oncol.* 2006; 29:290–297. [PubMed: 16755183]
111. Nakamura K, Shioyama Y, Kawashima M, et al. Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy. *Int J Radiat Oncol Biol Phys.* 2006; 65:1045–1050. [PubMed: 16682142]
112. Vikram B, Farr HW. Adjuvant radiation therapy in locally advanced head and neck cancer. *CA Cancer J Clin.* 1983; 33:134–138. [PubMed: 6404520]
113. Strong EW, Henschke UK, Nickson JJ, Frazell EL, Tollefsen HR, Hilaris BS. Preoperative x-ray therapy as an adjunct to radical neck dissection. *Cancer.* 1966; 19:1509–1516. [PubMed: 5925257]
114. Fu KK, Cooper JS, Marcial VA, et al. Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer. *Int J Radiat Oncol Biol Phys.* 1996; 35:425–438. [PubMed: 8655364]
115. Kramer S, Gelber RD, Snow JB, et al. Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of Study 73–03 of the Radiation Therapy Oncology Group. *Head Neck Surg.* 1987; 10:19–30. [PubMed: 3449477]
116. Vandenbrouck C, Sancho H, Le Fur R, Richard JM, Cachin Y. Results of a randomized clinical trial of preoperative irradiation versus postoperative in treatment of tumors of the hypopharynx. *Cancer.* 1977; 39:1445–1449. [PubMed: 322836]
117. Lavaf A, Genden EM, Cesaretti JA, Packer S, Kao J. Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma. *Cancer.* 2008; 112:535–543. [PubMed: 18076014]
118. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. *N Engl J Med.* 2004; 350:1945–1952. [PubMed: 15128894]
119. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. *N Engl J Med.* 2004; 350:1937–1944. [PubMed: 15128893]
120. Choong N, Vokes E. Expanding role of the medical oncologist in the management of head and neck cancer. *CA Cancer J Clin.* 2008; 58:32–53. [PubMed: 18096865]
121. Kasperts N, Slotman BJ, Leemans CR, de Bree R, Doornaert P, Langendijk JA. Results of postoperative reirradiation for recurrent or second primary head and neck carcinoma. *Cancer.* 2006; 106:1536–1547. [PubMed: 16518815]
122. Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. *Head Neck.* 2008; 30:281–288. [PubMed: 17764087]

123. Harrison LB. Applications of brachytherapy in head and neck cancer. *Semin Surg Oncol.* 1997; 13:177–184. [PubMed: 9143055]
124. Hepel JT, Syed AM, Puthawala A, Sharma A, Frankel P. Salvage high-dose-rate (HDR) brachytherapy for recurrent head-and-neck cancer. *Int J Radiat Oncol Biol Phys.* 2005; 62:1444–1450. [PubMed: 16029806]
125. Puthawala A, Nisar Syed AM, Gamie S, Chen YJ, Londrc A, Nixon V. Interstitial low-dose-rate brachytherapy as a salvage treatment for recurrent head-and-neck cancers: long-term results. *Int J Radiat Oncol Biol Phys.* 2001; 51:354–362. [PubMed: 11567809]
126. Kupferman ME, Morrison WH, Santillan AA, et al. The role of interstitial brachytherapy with salvage surgery for the management of recurrent head and neck cancers. *Cancer.* 2007; 109:2052–2057. [PubMed: 17407106]
127. Most MD, Allori AC, Hu K, et al. Feasibility of flap reconstruction in conjunction with intraoperative radiation therapy for advanced and recurrent head and neck cancer. *Laryngoscope.* 2008; 118:69–74. [PubMed: 18165718]
128. Withers HR. Biologic basis for altered fractionation schemes. *Cancer.* 1985; 55(9 suppl):2086–2095. [PubMed: 3919923]
129. Million RR, Parsons JT, Cassisi NJ. Twice-a-day irradiation technique for squamous cell carcinomas of the head and neck. *Cancer.* 1985; 55(9 suppl):2096–2099. [PubMed: 3919924]
130. Wang CC, Blitzer PH, Suit HD. Twice-a-day radiation therapy for cancer of the head and neck. *Cancer.* 1985; 55(9 suppl):2100–2104. [PubMed: 3919925]
131. Salama JK, Seiwert TY, Vokes EE. Chemoradiotherapy for locally advanced head and neck cancer. *J Clin Oncol.* 2007; 25:4118–4126. [PubMed: 17827462]
132. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. *Acta Oncol.* 1988; 27:131–146. [PubMed: 3390344]
133. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. *Lancet.* 2006; 368:843–854. [PubMed: 16950362]
134. Sanguineti G, Richetti A, Bignardi M, et al. Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter phase III study. *Int J Radiat Oncol Biol Phys.* 2005; 61:762–771. [PubMed: 15708255]
135. Mendenhall WM, Amdur RJ, Palta JR. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. *J Clin Oncol.* 2006; 24:2618–2623. [PubMed: 16763274]
136. Lee N, Puri DR, Blanco AI, Chao KS. Intensity-modulated radiation therapy in head and neck cancers: an update. *Head Neck.* 2007; 29:387–400. [PubMed: 16358297]
137. Schwartz DL, Ford EC, Rajendran J, et al. FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. *Head Neck.* 2005; 27:478–487. [PubMed: 15772953]
138. Mell LK, Mehrotra AK, Mundt AJ. Intensity-modulated radiation therapy use in the US, 2004. *Cancer.* 2005; 104:1296–1303. [PubMed: 16078260]
139. Mell LK, Roeske JC, Mundt AJ. A survey of intensity-modulated radiation therapy use in the United States. *Cancer.* 2003; 98:204–211. [PubMed: 12833473]
140. Kaplan ID, Adler JR, Hicks WL Jr, Fee WE, Goffinet DR. Radiosurgery for palliation of base of skull recurrences from head and neck cancers. *Cancer.* 1992; 70:1980–1984. [PubMed: 1525775]
141. Ryu S, Khan M, Yin FF, et al. Image-guided radiosurgery of head and neck cancers. *Otolaryngol Head Neck Surg.* 2004; 130:690–697. [PubMed: 15195054]
142. Voynov G, Heron DE, Burton S, et al. Frameless stereotactic radiosurgery for recurrent head and neck carcinoma. *Technol Cancer Res Treat.* 2006; 5:529–535. [PubMed: 16981796]
143. Watne AL. Treatment alternatives. Head and neck cancers. *Cancer.* 1984; 54(11 suppl):2673–2681. [PubMed: 6498757]
144. Weaver Z 3rd, Thomas CG Jr. Further studies on topical chemotherapy in experimentally implanted cancer. *Cancer.* 1962; 15:584–590. [PubMed: 14005404]
145. Burke E, Sako K. Cancer cells in wound washings in head and neck surgery. *Cancer.* 1960; 13:772–774. [PubMed: 13806131]

146. Smith RR, Thomas LB, Hilberg AW. Cancer cell contamination of operative wounds. *Cancer*. 1958; 11:53–62. [PubMed: 13500297]
147. Sullivan RD, Miller E, Sikes MP. Antimetabolite-metabolite combination cancer chemotherapy. Effects of intraarterial methotrexate-intramuscular Citrovorum factor therapy in human cancer. *Cancer*. 1959; 12:1248–1262. [PubMed: 13835650]
148. Rogers LS. Cancer chemotherapy by continuous intra-arterial infusion. Experience of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Infusion Study Group. *Cancer*. 1964; 17:1365–1380. [PubMed: 14223752]
149. Warren SE, Van Prohaska J. An apparatus for intraarterial chemotherapy of cancer. *Cancer*. 1963; 16:564–566. [PubMed: 13998998]
150. Feder RJ, Acquarelli MJ, Gordon HE. Complications inherent in continuous intra-arterial chemotherapy of head and neck carcinoma. *Cancer*. 1964; 17:1385–1390. [PubMed: 14223754]
151. Bernier J, Vermorken JB, Koch WM. Adjuvant therapy in patients with resected poor-risk head and neck cancer. *J Clin Oncol*. 2006; 24:2629–2635. [PubMed: 16763276]
152. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. *J Clin Oncol*. 2004; 22:1743–1752. [PubMed: 15117998]
153. Gollin FF, Johnson RO. Preirradiation 5-fluorouracil infusion in advanced head and neck carcinomas. *Cancer*. 1971; 27:768–770. [PubMed: 5574067]
154. Ensley J, Crissman J, Kish J, et al. The impact of conventional morphologic analysis on response rates and survival in patients with advanced head and neck cancers treated initially with cisplatin-containing combination chemotherapy. *Cancer*. 1986; 57:711–717. [PubMed: 3943009]
155. Hong WK, Shapshay SM, Bhutani R, et al. Induction chemotherapy in advanced squamous head and neck carcinoma with high-dose cis-platinum and bleomycin infusion. *Cancer*. 1979; 44:19–25. [PubMed: 88255]
156. Leitner SP, Bosl GJ, Strong EW, et al. A pilot study of cisplatin-vinblastine as the initial treatment of advanced head and neck cancer. *Cancer*. 1986; 58:1014–1017. [PubMed: 3731034]
157. Milazzo J, Mohit-Tabatabai MA, Hill GJ, et al. Preoperative intra-arterial infusion chemotherapy for advanced squamous cell carcinoma of the mouth and oropharynx. *Cancer*. 1985; 56:1014–1017. [PubMed: 4016692]
158. Rooney M, Kish J, Jacobs J, et al. Improved complete response rate and survival in advanced head and neck cancer after 3-course induction therapy with 120-hour 5-FU infusion and cisplatin. *Cancer*. 1985; 55:1123–1128. [PubMed: 4038469]
159. Schuller DE, Wilson HE, Smith RE, Batley F, James AD. Preoperative reductive chemotherapy for locally advanced carcinoma of the oral cavity, oropharynx, and hypopharynx. *Cancer*. 1983; 51:15–19. [PubMed: 6185194]
160. Vogl SE, Lerner H, Kaplan BH, Camacho F, Cinberg J, Schoenfeld D. Mitomycin-C, methotrexate, bleomycin and cis-diamminedichloroplatinum II in the chemotherapy of advanced squamous cancer of the head and neck. *Cancer*. 1982; 50:6–9. [PubMed: 6177393]
161. Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program. *Cancer*. 1987; 60:301–311. [No authors listed]. [PubMed: 2885080]
162. Schuller DE, Metch B, Stein DW, Mattox D, McCracken JD. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. *Laryngoscope*. 1988; 98:1205–1211. [PubMed: 3054373]
163. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. *N Engl J Med*. 1991; 324:1685–1690. [No authors listed]. [PubMed: 2034244]
164. Lefebvre JL, Chevalier D, Lubinski B, Kirkpatrick A, Collette L, Sakhmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. *J Natl Cancer Inst*. 1996; 88:890–899. [PubMed: 8656441]
165. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. *N Engl J Med*. 2003; 349:2091–2098. [PubMed: 14645636]

166. Weber RS, Berkey BA, Forastiere A, et al. Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group Trial 91-11. *Arch Otolaryngol Head Neck Surg.* 2003; 129:44-49. [PubMed: 12525193]
167. Argiris A. Induction chemotherapy for head and neck cancer: will history repeat itself? *J Natl Compr Canc Netw.* 2005; 3:393-403. [PubMed: 16002005]
168. Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. *Ann Oncol.* 2004; 15:1179-1186. [PubMed: 15277256]
169. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: 3 meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. *Lancet.* 2000; 355:949-955. [PubMed: 10768432]
170. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. *J Clin Oncol.* 2005; 23:8636-8645. [PubMed: 16275937]
171. Posner MR, Herschock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. *N Engl J Med.* 2007; 357:1705-1715. [PubMed: 17960013]
172. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. *N Engl J Med.* 2007; 357:1695-1704. [PubMed: 17960012]
173. University of Chicago. Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE): clinicaltrials.gov identifier NCT00117572. Accessed on August 12, 2008. Available at: <http://clinicaltrials.gov/ct2/show/NCT00117572>
174. University of Medicine and Dentistry New Jersey, Dana-Farber Cancer Institute. Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer (Paradigm Trial): clinicaltrials.gov identifier NCT00705068. Accessed on August 12, 2008 Available at: <http://clinicaltrials.gov/ct2/show/NCT00705068>
175. Laramore GE, Scott CB, al-Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. *Int J Radiat Oncol Biol Phys.* 1992; 23:705-713. [PubMed: 1618662]
176. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. *J Clin Oncol.* 2006; 24:2644-2652. [PubMed: 16763278]
177. Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? *Laryngoscope.* 2000; 110(3 pt 2 suppl 93):1-18. [PubMed: 10714711]
178. Janot F, De Raucourt D, Castaing M, et al. GETTEC and GORTEC. Re-irradiation combined with chemotherapy after salvage surgery in head and neck carcinoma: a randomized trial from the GETTEC and GORTEC groups [abstract]. 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). *J Clin Oncol.* 2006; 24(18S):5508.
179. Vokes EE, Weichselbaum RR. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. *J Clin Oncol.* 1990; 8:911-934. [PubMed: 2185342]
180. Kligerman M. The role of combination radiation and chemotherapy. *Cancer.* 1960; 13(S6):147-157.
181. Brizel DM, Esclamado R. Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. *J Clin Oncol.* 2006; 24:2612-2617. [PubMed: 16763273]
182. Adelstein DJ. Recent randomized trials of chemoradiation in the management of locally advanced head and neck cancer. *Curr Opin Oncol.* 1998; 10:213-218. [PubMed: 9619357]
183. Al-Sarraf M, Pajak TF, Marcial VA, et al. Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG Study. *Cancer.* 1987; 59:259-265. [PubMed: 3802013]

184. Crissman JD, Pajak TF, Zarbo RJ, Marcial VA, Al-Sarraf M. Improved response and survival to combined cisplatin and radiation in nonkeratinizing squamous cell carcinomas of the head and neck. An RTOG study of 114 advanced stage tumors. *Cancer*. 1987; 59:1391–1397. [PubMed: 2434208]
185. Marcial VA, Pajak TF, Mohiuddin M, et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the Radiation Therapy Oncology Group Study 81–17. *Cancer*. 1990; 66:1861–1868. [PubMed: 2224782]
186. Adelstein DJ, Saxton JP, Lavertu P, et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. *Head Neck*. 1997; 19:567–575. [PubMed: 9323144]
187. Bourhis J, Amand C, Pignon J-P. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy [abstract]. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). *J Clin Oncol*. 2004; 22(14S) Abstract 5505.
188. Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of 8 randomized trials and 1753 patients. *Int J Radiat Oncol Biol Phys*. 2006; 64:47–56. [PubMed: 16377415]
189. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup Study 0099. *J Clin Oncol*. 1998; 16:1310–1317. [PubMed: 9552031]
190. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. *J Natl Cancer Inst*. 1999; 91:2081–2086. [PubMed: 10601378]
191. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (22931) and RTOG (9501). *Head Neck*. 2005; 27:843–850. [PubMed: 16161069]
192. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. *Nat Rev Cancer*. 2005; 5:172–183. [PubMed: 15719031]
193. Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. *JAMA*. 2007; 298:70–82. [PubMed: 17609492]
194. Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor- α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. *Cancer*. 1996; 78:1284–1292. [PubMed: 8826952]
195. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF- α and EGFR protein in head and neck squamous cell carcinoma and patient survival. *J Natl Cancer Inst*. 1998; 90:824–832. [PubMed: 9625170]
196. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by antiepidermal growth factor receptor monoclonal antibodies. *Cancer Res*. 1984; 44:1002–1007. [PubMed: 6318979]
197. Mendelsohn J. Growth factor receptors as targets for anti-tumor therapy with monoclonal antibodies. *Prog Allergy*. 1988; 45:147–160. [PubMed: 3064094]
198. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. *N Engl J Med*. 2006; 354:567–578. [PubMed: 16467544]
199. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. *J Clin Oncol*. 2006; 24:1072–1078. [PubMed: 16505426]
200. Wainberg Z, Hecht JR. Panitumumab in colon cancer: a review and summary of ongoing trials. *Expert Opin Biol Ther*. 2006; 6:1229–1235. [PubMed: 17049019]

201. Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. *J Clin Oncol.* 2006; 24:2659–2665. [PubMed: 16763280]
202. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. *J Clin Oncol.* 2003; 21:1980–1987. [PubMed: 12743152]
203. Siu LL. Promising new targeted agents in head and neck cancer. *Int J Radiat Oncol Biol Phys.* 2007; 69(2 suppl):S59–S60. [PubMed: 17848297]
204. Ferrara N. VEGF as a therapeutic target in cancer. *Oncology.* 2005; 69(suppl 3):11–16. [PubMed: 16301831]
205. Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. *Natl Clin Pract Oncol.* 2007; 4:156–171.
206. Chacko DC, Hendrickson FR, Fisher A. Definitive irradiation of T1-T4N0 larynx cancer. *Cancer.* 1983; 51:994–1000. [PubMed: 6821874]
207. Pfister DG, Laurie SA, Weinstein GS, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. *J Clin Oncol.* 2006; 24:3693–3704. [PubMed: 16832122]
208. Jones AS, Fish B, Fenton JE, Husband DJ. The treatment of early laryngeal cancers (T1–T2 N0): surgery or irradiation? *Head Neck.* 2004; 26:127–135. [PubMed: 14762881]
209. Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Villaret DB. Management of T1–T2 glottic carcinomas. *Cancer.* 2004; 100:1786–1792. [PubMed: 15112257]
210. Wang CC. Radiotherapeutic management and results of T1N0, T2N0 carcinoma of the oral tongue: evaluation of boost techniques. *Int J Radiat Oncol Biol Phys.* 1989; 17:287–291. [PubMed: 2502509]
211. Wendt CD, Peters LJ, Delclos L, et al. Primary radiotherapy in the treatment of stage I and II oral tongue cancers: importance of the proportion of therapy delivered with interstitial therapy. *Int J Radiat Oncol Biol Phys.* 1990; 18:1287–1292. [PubMed: 2370178]
212. de Braud F, Heilbrun LK, Ahmed K, et al. Metastatic squamous cell carcinoma of an unknown primary localized to the neck. Advantages of an aggressive treatment. *Cancer.* 1989; 64:510–515. [PubMed: 2736495]
213. Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. *Mayo Clin Proc.* 2008; 83:489–501. [PubMed: 18380996]
214. Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. *Cancer.* 2004; 101:2641–2649. [PubMed: 15517576]
215. Allal AS, Nicoucar K, Mach N, Dulguerov P. Quality of life in patients with oropharynx carcinomas: assessment after accelerated radiotherapy with or without chemotherapy versus radical surgery and postoperative radiotherapy. *Head Neck.* 2003; 25:833–839. discussion 839–840. [PubMed: 12966507]
216. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and 2 schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. *J Clin Oncol.* 2003; 21:92–98. [PubMed: 12506176]
217. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. *Head Neck.* 2001; 23:579–589. [PubMed: 11400247]
218. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. *J Clin Oncol.* 2004; 22:69–76. [PubMed: 14657228]
219. Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. *BMC Cancer [serial online].* 2006; 6:28.

220. Radiation Oncology Group. A randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab (C225) [followed by surgery for selected patients] for stage III and IV head and neck carcinoma (clinical trial NCT00265941). Accessed on August 12, 2008. Available at: <http://clinicaltrials.gov/ct2/show/NCT00265941>
221. Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer. *Cancer*. 2000; 88:2398–2424. [PubMed: 10820364]
222. Hoffman HT, Porter K, Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. *Laryngoscope*. 2006; 116(9 pt 2 suppl 111):1–13. [PubMed: 16946667]
223. Chen AY, Halpern M. Factors predictive of survival in advanced laryngeal cancer. *Arch Otolaryngol Head Neck Surg*. 2007; 133:1270–1276. [PubMed: 18086971]
224. List MA, Stracks J, Colangelo L, et al. How do head and neck cancer patients prioritize treatment outcomes before initiating treatment? *J Clin Oncol*. 2000; 18:877–884. [PubMed: 10673531]
225. Karnofsky D, Abelmann W, Craver L, Burchenal J. The use of the nitrogen mustards in the palliative treatment of carcinoma. *Cancer*. 1948; 1:634–656.
226. Abendstein H, Nordgren M, Boysen M, et al. Quality of life and head and neck cancer: a 5 year prospective study. *Laryngoscope*. 2005; 115:2183–2192. [PubMed: 16369164]
227. Sherman AC, Simonton S, Adams DC, Vural E, Owens B, Hanna E. Assessing quality of life in patients with head and neck cancer: cross-validation of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Head and Neck module (QLQ-H&N35). *Arch Otolaryngol Head Neck Surg*. 2000; 126:459–467. [PubMed: 10772298]

FIGURE 1.

Slaughter et al introduced the concept of ‘field cancerization’ in *Cancer* in 1953.⁶ This material is reproduced with permission of Wiley-Liss, Inc, a subsidiary of John Wiley & Sons, Inc. *Cancer*. September 1953;6(5):963–968. Copyright 1953 American Cancer Society.

FIGURE 2.

Lymph node levels of the neck. A radical neck dissection (RND) includes all lymph node levels I through V as well as the internal jugular vein, the spinal accessory nerve, and the sternocleidomastoid muscle. A modified RND (MRND) includes the same lymph node levels as an RND but spares 1 or more of the nonlymphatic structures. The selective neck dissection preserves 1 or more of the lymph node groups normally included in an MRND. Therapeutic neck dissection refers to treatment for clinically positive disease. Elective neck dissection is for the prophylactic removal of lymph node levels based on the known risk of occult metastases.

FIGURE 3.

The radical neck dissection as described by Hayes Martin in 1951.³⁹ N indicates nerve; M, muscle; V, vein; Int. jug. V., internal jugular vein, Ant., anterior. This material is reproduced with permission of Wiley-Liss, Inc, a subsidiary of John Wiley & Sons, Inc. *Cancer*. May 1951;4(3):441–499. Copyright 1951 American Cancer Society.

PERFORMANCE STATUS		
<i>Definition</i>	<i>%</i>	<i>Criteria</i>
Able to carry on normal activity and to work. No special care is needed.	100	Normal; no complaints; no evidence of disease.
	90	Able to carry on normal activity; minor signs or symptoms of disease.
	80	Normal activity with effort; some signs or symptoms of disease.
Unable to work. Able to live at home, care for most personal needs. A varying amount of assistance is needed.	70	Cares for self. Unable to carry on normal activity or to do active work.
	60	Requires occasional assistance, but is able to care for most of his needs.
	50	Requires considerable assistance and frequent medical care.
Unable to care for self. Requires equivalent of institutional or hospital care. Disease may be progressing rapidly.	40	Disabled; requires special care and assistance.
	30	Severely disabled; hospitalization is indicated although death not imminent.
	20	Very sick; hospitalization necessary; active supportive treatment necessary.
	10	Moribund; fatal processes progressing rapidly.
	0	Dead.

FIGURE 4.

The Karnofsky performance status score as introduced in 1948.²²⁵ This material is reproduced with permission of Wiley-Liss, Inc, a subsidiary of John Wiley & Sons, Inc. *Cancer*. November 1948;1(4):634–656. Copyright 1948 American Cancer Society.

TABLE 1**Landmark Randomized Controlled Trials With Cisplatin With or Without 5-Fluorouracil**

Year	Reference(s)	Cancer Type	Regimen
1991	VA Laryngeal Cancer Study, 1991163	Larynx	Induction cisplatin and 5-FU followed by radiation in responders vs surgery followed by radiation
1996	Lefebvre, 1996164 (EORTC 24891)	Hypopharynx	Induction cisplatin and 5-FU followed by radiation in responders vs surgery followed by radiation
1998	Al-Sarraf, 1998189 (Intergroup 00-99)	Nasopharynx	Concurrent cisplatin and radiotherapy followed by adjuvant cisplatin and 5-FU vs radiation alone
1999	Calais, 1999,190 Denis, 2004218 (GORTEC 94-01)	Oropharynx	Concurrent carboplatin, 5-FU, and radiation vs radiation alone
2003	Forastiere, 2003165 (RTOG 91-11)	Larynx	Induction cisplatin plus 5-FU followed by radiation in responders vs concurrent cisplatin and radiation vs radiation alone
2004	Cooper, 2004119 (RTOG 9501)	Oral cavity, oropharynx, hypopharynx, or larynx	Postoperative concurrent cisplatin and radiation vs postoperative radiation alone
2004	Bernier, 2004118 (EORTC 22931)	Oral cavity, oropharynx, hypopharynx, or larynx	Postoperative concurrent cisplatin and radiation vs postoperative radiation alone

VA indicates Veterans Administration; 5-FU, 5-fluorouracil; EORTC, European Organization for Research and Treatment of Cancer; GORTEC, French Head and Neck Radiation Oncology Radiotherapy Group; RTOG, Radiation Oncology Group.

TABLE 2**Important Head and Neck Cancer Publications in Cancer**

Year	Reference(s)	Notes
1948	Karnofsky, 1948 ²²⁵	Introduction of performance status scale
1951	Martin, 1951 ³⁹	Description and application of radical neck dissection
1953	Slaughter, 1953 ⁶	Concept of field cancerization
1956–1971	Hoffmann & Wynder, 1971 ¹¹⁰ ; Wynder, 1957, ^{11,15} 1958 ¹⁹ , 1959, ²⁰ 1968 ¹⁷ ; Wynder & Hoffmann, 1959, ¹² 1961, ¹³ 1969 ¹⁴ ; Wynder & Mann, 1957 ¹⁶ ; Wynder & Wright, 1957 ¹⁸	Series confirming tobacco carcinogenesis
1960	Gould, 1960 ⁶⁴	Concept of sentinel lymph node biopsy
1972	Lindberg, 1972 ⁵⁰	Distribution patterns of cervical metastases
1987	Head and Neck Contracts Group, 1987 ¹⁶¹	Randomized trial of induction chemotherapy
1995	Shindoh, 1995 ²⁹	Identification of HPV in oral squamous cell carcinoma

HPV indicates human papillomavirus.